好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Exploring the Role of Carotid Stenting in the Treatment of Symptomatic Carotid Webs: A Single-center Case Series
Cerebrovascular Disease and Interventional Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
5-019

Describe safety and short-term clinical and imaging outcomes after carotid artery stenting (CAS) for symptomatic carotid web.

Carotid web, a shelf-like intimal projection at the internal carotid artery bulb, is an underrecognized cause of embolic stroke in young individuals. Observational data indicate a high rate of recurrence with medical therapy, while revascularization procedures, such as endarterectomy and CAS, seem to reduce this risk. Case series of CAS show a high rate of technical success and low complications.

Retrospective single-center case series of adults who experienced strokes and were found to have an ipsilateral carotid web identified on CTA/DSA imaging, undergoing CAS. We collected data on demographic, therapeutic, clinical, and radiographic variables at the time of diagnosis and during follow-up. The analysis was descriptive.

Five young patients (median age 47 [IQR 29.5–53], 40% women) presented with embolic-appearing infarcts (40% LVO) and ipsilateral carotid web; median stenosis was 40% [IQR 35 - 67.5], and NIHSS scores median 4 [IQR 3-5]. All patients received aspirin plus clopidogrel before the procedure. Carotid artery stenting was performed a median of 114 days (73–140) from the index stroke; IV thrombolysis was used in 1/5. Technical success was 5/5; and balloon expansion was required in 3/5 to optimize stent apposition. Two patients developed mild vasospasm, which was successfully treated with IA nitroglycerin. At 90 days, functional outcomes were favorable (mRS 0–1 in 5/5), and during imaging follow-up, there were no recurrent ischemic events, no ICH, and no in-stent restenosis

CAS for carotid web in young stroke patients appears feasible and safe, showing good 90-day outcomes and early vessel patency; consistent with prior reports, revascularization is reasonable when an embolic mechanism is likely, though larger prospective studies are needed.

Authors/Disclosures
Leonardo Cruz, MD (University of Iowa)
PRESENTER
Dr. Cruz has nothing to disclose.
Leonardo Romero Gamarra, MD Dr. Romero Gamarra has nothing to disclose.
Nestor C. Flores-Rodriguez, RN Ms. Flores-Rodriguez has nothing to disclose.
Danny Barrientos, MD (Instituto Nacional De Ciencias Neurologicas) Dr. Barrientos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for boehringer ingelheim.